Effect of Chronic Inflammation on Myocardial Perfusion and Function
-
- STATUS
- Recruiting
-
- End date
- Jul 1, 2025
-
- participants needed
- 168
-
- sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Summary
- Background
Heart failure (HF) is a public health burden. Studies have shown a link between inflammation, myocardial dysfunction, and HF. Researchers want to use psoriasis as a disease model of chronic inflammation to further study the link between inflammation and myocardial dysfunction.
- Objective
To learn if chronic inflammation affects the heart and if taking a biological medicine for chronic inflammation helps improve how the heart works.
- Eligibility
Adults ages 18 and older who have moderate to severe psoriasis, and healthy adult volunteers.
- Design
Participants will be screened with a medical history. They may take a pregnancy test.
Healthy volunteers will have 1 visit. Those with psoriasis will have a second visit 1 year later.
Participants may give blood samples. They may have a heart function test. They may have a heart imaging test, and may get a contrast agent. If so, it will be injected into a vein.
Participants may have positron emission tomography/computed tomography tests. They will lie on their back on a padded table with their arms straight overhead. They may get radioactive drugs through an intravenous (IV) catheter. They will get stress medicines through the IV. These drugs mimic exercise and increase blood flow through the heart.
Participants may have cardiac magnetic resonance imaging. The scanner is a large tube. Participants will lie on a table that slides in and out of the tube. They will get gadolinium contrast in a vein to improve the pictures. They may get stress medicines. Coils will be used to help make the pictures.
Participation for healthy volunteers will last 1-2 days. Participation for those with psoriasis will last 14 months.
...
Description
Study Description:
Heart failure (HF) remains a significant public health burden despite expanding and improving treatment options. Clinical and pre-clinical studies have demonstrated compelling relationships between inflammation, myocardial dysfunction, HF and adverse clinical outcomes. In this study to be conducted at the NIH Clinical Center, we propose to utilize psoriasis as a disease model to study how chronic inflammation effects myocardial perfusion, measured by myocardial flow reserve (MFR) on positron emission tomography (PET) and cardiac MRI (CMR), and myocardial function and tissue composition measured by multi-modality cardiovascular imaging.
- Objectives
-
- To test the hypothesis that chronic inflammation is a driver of perturbances in myocardial perfusion, function, and tissue composition
- To test the hypothesis that biologic treatment for psoriasis will be associated with longitudinal improvement in myocardial perfusion, function, and tissue composition
- To characterize immune cell subsets and their association with myocardial perfusion, function, and tissue composition in chronic inflammation
- To explore how chronic inflammation may alter myocardial energetics and metabolism
- Endpoints
Primary outcomes will be:
Myocardial perfusion, as assessed by myocardial flow reserve (MFR), in subjects with moderate to severe psoriasis compared to matched healthy controls.
Secondary outcomes will be:
Change in MFR in subjects with psoriasis on biologic therapy at 1 year follow-up compared to baseline.
Diastolic function (on echocardiogram), myocardial mechanics (on echocardiogram and CMR), myocardial edema and inflammation, and interstitial fibrosis (on CMR) in subjects with moderate to severe psoriasis compared to matched healthy controls.
Change in diastolic function, myocardial mechanics, myocardial edema and inflammation, and interstitial fibrosis in subjects with psoriasis on biologic therapy at 1 year follow- up
Exploratory outcomes will be:
Immune cell subsets by flow cytometry in subjects with 7 moderate to severe psoriasis compared to matched healthy controls
Rest and stress left ventricular oxygen consumption (MVO2) in subjects with moderate to severe psoriasis compared to matched healthy controls
Details
| Condition | Psoriasis |
|---|---|
| Clinical Study Identifier | NCT04870827 |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Last Modified on | 4 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer